76
|
Dimmock M, Mendes LC, Albluwi S, Paul C, Thomas C, Laurencin S, Cousty S. An oral manifestation of IBD: Pyostomatitis vegetant, about two cases. JOURNAL OF STOMATOLOGY, ORAL AND MAXILLOFACIAL SURGERY 2019; 120:375-377. [PMID: 31035024 DOI: 10.1016/j.jormas.2019.04.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2019] [Revised: 04/10/2019] [Accepted: 04/21/2019] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Pyostomatitis vegetan (PV) is often associated with chronic inflammatory bowel disease (IBD). OBSERVATION Two cases of PV are reported. Case number 1 is a 66-year-old patient treated with infliximab for ulcerative colitis (UC). He presented himself with rapidly progressing crusty, whitish, ulcerated lesions on his lips. Diagnosis of PV was made after biopsy. Regression of oral lesions was favourable with local application of dermocorticoids while continuing infliximab treatment. Case number 2 is a 20-year-old patient treated with infliximab for Crohn's disease (CD). She had cheilitis and angular cheilitis. Diagnosis of PV was made after biopsy. The evolution was favourable after treating with topical dermocorticoids. DISCUSSION PV is associated in 75% of the cases with IBD. The digestive check-up is systematic. Diagnostic delay is often noted. Topical dermocorticoids are the first line of therapy.
Collapse
|
77
|
Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol 2019; 178:1003-1005. [PMID: 29785816 DOI: 10.1111/bjd.16497] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
78
|
Tauber M, Apoil PA, Richet C, Laurent J, De Bonnecaze G, Mouchon E, Cassagne M, Marguery MC, Hegazy S, Konstantinou MP, Severino M, Uthurriague C, Giordano-Labadie F, Didier A, Paul C. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice. Br J Dermatol 2019; 180:1551-1552. [PMID: 30633329 DOI: 10.1111/bjd.17629] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
79
|
Leshem YA, Bissonnette R, Paul C, Silverberg JI, Irvine AD, Paller AS, Cork MJ, Guttman-Yassky E. Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. J Eur Acad Dermatol Venereol 2019; 33:807-815. [PMID: 30859656 PMCID: PMC6594032 DOI: 10.1111/jdv.15480] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Accepted: 01/04/2019] [Indexed: 12/14/2022]
Abstract
BACKGROUND As novel systemic therapeutics for patients with atopic dermatitis (AD) are developed, ethical and methodological concerns regarding placebo-controlled-trials (PCT) have surfaced. OBJECTIVE To guide the design and implementation of PCT in AD, focusing on trials with systemic medications. METHODS A subgroup of the International Eczema Council (IEC) developed a consensus e-survey, which was disseminated to IEC members. RESULTS The response rate was 43/82 (52%). Consensus was reached on 24/27 statements and on 3/11 options from multiple-selection statements, including: performing monotherapy studies in proof-of-concept phases; avoiding concomitant topical corticosteroids or calcineurin inhibitors until a predefined timepoint as rescue (borderline consensus); selection of sites and assessors with recognized expertise in AD clinical trials; clear definition and identification of baseline disease severity; minimizing time and proportion of patients on placebo; using daily emollients with several options provided; instigating open-label extension studies for enrolment after a predefined timepoint; and including outcomes which set a higher bar for disease clearance. CONCLUSION Conducting PCT in AD requires balancing several, sometimes opposing principles, including ethics, methodology, regulatory requirements and real-world needs. This paper can provide a framework for conducting PCT with systemic medications for patients with AD.
Collapse
|
80
|
Mabrouk N, Racoeur C, Dondaine L, Shann J, Ghiringhelli F, Chouchane L, Bettaieb A, Paul C. Immune and mutational landscape in triple negative breast cancer and its evolution during neoadjuvant chemotherapy associated or not with GTN and anti-PD-1. Eur J Cancer 2019. [DOI: 10.1016/j.ejca.2019.01.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
81
|
Sampogna F, Puig L, Spuls P, Girolomoni G, Radtke M, Kirby B, Brunori M, Bergmans P, Smirnov P, Rundle J, Castiglia A, Lavie F, Paul C. Alexithymia reversion in psoriasis. Br J Dermatol 2019. [DOI: 10.1111/bjd.17479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
82
|
Sampogna F, Puig L, Spuls P, Girolomoni G, Radtke M, Kirby B, Brunori M, Bergmans P, Smirnov P, Rundle J, Castiglia A, Lavie F, Paul C. 银屑病患者的述情障碍逆转. Br J Dermatol 2019. [DOI: 10.1111/bjd.17492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
83
|
Machado dos Santos P, O’Caoimh R, Svendrovski A, Casanovas C, Orfila Pernas F, Illario M, Molloy W, Paul C. The RAPid COmmunity COGnitive screening Programme (RAPCOG): Developing the Portuguese version of the Quick Mild Cognitive Impairment (Q mci-P) screen as part of the EIP on AHA Twinning Scheme. Transl Med UniSa 2019; 19:82-89. [PMID: 31360671 PMCID: PMC6581493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
As populations age and the prevalence of cognitive impairment increases, healthcare professionals and researchers require short, validated cognitive screening instruments (CSIs). As part the EIP-on-AHA Twinning Support Scheme (2016), four reference sites developed the RAPid COmmunity COGnitive screening Programme (RAPCOG) twinning project to validate translated versions of the Quick Mild Cognitive Impairment (Qmci) screen that could be adapted quickly for use with future eHealth screening and assessment programmes. Here we present the cultural adaption and translation of the Qmci-Portuguese (Qmci-P) screen as part of RAPCOG and explore its subsequent validation against two commonly-used CSIs (MMSE-P and MoCA-P) with 93 participants aged ≥65, attending ten day care centres or resident in two long-term care institutions; median age 74 (+/-15), 66% female. The Qmci-P's internal consistency was high (Cronbach's Alpha 0.82), compared with the MoCA (0.79) and SMMSE (0.54). Qmci-P screen scores moderately correlated with the SMMSE (r=0.61, 95% CI:0.45-0.72, p<0.001) and MoCA (r=0.63, 95% CI:0.36-0.80, p<0.001). The Qmci-P screen demonstrates high internal consistency and concurrent validity against more established CSIs and given its brevity (3-5mins), may be preferable for use in community settings. This project shows the potential of the EIP-on-AHA Twinning initiative to promote the scaling-up of innovative good practices.
Collapse
|
84
|
Augustin M, Wegtowska J, Lebwohl M, Paul C, Piguet V, Sofen H, Blauvelt A, Peterson L, Arendt C, Rolleri R. Clinical Response in Plaque Psoriasis Patients Switching from Etanercept to Certolizumab Pegol in a Phase 3, Randomized, Controlled Study. ACTA ACUST UNITED AC 2018. [DOI: 10.25251/skin.2.supp.87] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Abstract not available. Disclosures: Study sponsored by Dermira. Copyright 2018 SKIN
Collapse
|
85
|
Augustin M, Wegtowska J, Lebwohl M, Paul C, Piguet V, Sofen H, Blauvelt A, Peterson L, Al. E. Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). ACTA ACUST UNITED AC 2018. [DOI: 10.25251/skin.2.supp.88] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Abstract not available. Disclosures: Study sponsored by Dermira.Copyright 2018 SKIN
Collapse
|
86
|
Hebert V, Vermeulin T, Prost-Squarcioni C, Picard-Dahan C, Duvert-Lehembre S, Bruno L, Marie-Aleth R, Bernard P, Dupuy A, Bouaziz JD, Oro S, Dalac-Rat S, Delaporte E, Avenel-Audran M, Sassolas B, Alexandre M, Caux F, D’Incan M, Bedane C, Quereux G, Machet L, Dereure O, Skowron F, Franck N, Beylot-Barry M, Doutre MS, Debarbieux S, Jullien D, Misery L, Musette P, Paul C, Vabres P, Bénéton N, Dupin N, Houivet E, Joly P. Comparaison des coûts de santé du traitement de première ligne par rituximab par rapport à la corticothérapie standard chez les patients pemphigus nouvellement diagnostiqués. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
87
|
Sampogna F, Puig L, Spuls P, Girolomoni G, Radke M, Kirby B, Bergmans P, Smirnov P, Rundle J, Castiglia A, Lavie F, Paul C. L’alexithymie est réversible sous traitement dans le psoriasis modéré à sévère : une étude prospective multicentrique. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
88
|
Jendoubi F, Severino M, Paul C, Bulai-Livideanu C. Omalizumab comme traitement de la pathologie mastocytaire : revue systématique de la littérature. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
89
|
Masson Regnault M, Castaneda Sanabria J, Tran M, Beylot-Barry M, Bachelez H, Beneton N, Chosidow O, Dupuy A, Joly P, Jullien D, Mahé E, Richard MA, Viguier M, Tubach F, Sbidian E, Paul C. Les patients de la vraie vie peuvent-ils être inclus dans les études cliniques évaluant des biologiques ? Analyse dans la cohorte PsoBioTeq. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
90
|
Touhouche A, Arthozoul M, Bulai-Livideanu C, Tauber M, Paul C. Premier cas de myonécrose post-vaccinale. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
91
|
Fradet M, Hegazy S, Bulai-Livideanu C, Hardy J, Godillot C, Godeau M, Touhouche A, Deilhes F, Casassa E, Borjesson C, Albluwi S, Balica S, Maza A, Thomas-Pfaab M, Aquilina C, Gall Y, Chaput B, Paul C, Konstantinou MP. Laser épilatoire alexandrite dans le cadre de la prise en charge de l’hidradénite suppurée. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
92
|
Cura P, Guinard E, Florian D, Lamant L, Malloizel J, Bulai Livideanu C, Chaput B, Paul C, Nicolas M. Une association d’ulcères extensifs et d’une sclérose cutanée révélatrice de siliconomes. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
93
|
Godillot C, Konstantinou MP, Gallini A, Paul C. Comment évaluer la satisfaction des patients concernant leur prise en charge : revue systématique de la littérature. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
94
|
Tauber M, Apoil PA, Richet C, Laurent J, De Bonnecaze G, Mouchon E, Cassagne M, Marguery MC, Hegazy S, Konstantinou M, Severino-Freire M, Uthurriague C, Giordano-Labadie F, Didier A, Paul C. Efficacité du dupilumab sur l’eczéma et les comorbidités atopiques en vie réelle : absence de corrélation avec la diminution des IgE totales et spécifiques. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
95
|
Cousty S, Konstantinou M, Laurencin S, Paul C, Bulai Livideanu C. Le laser vasculaire Nd-YAG : une alternative thérapeutique pour les grands lacs veineux de la muqueuse buccale. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
96
|
Sampogna F, Puig L, Spuls P, Girolomoni G, Radtke M, Kirby B, Brunori M, Bergmans P, Smirnov P, Rundle J, Castiglia A, Lavie F, Paul C. Reversibility of alexithymia with effective treatment of moderate‐to‐severe psoriasis: longitudinal data from
EPIDEPSO. Br J Dermatol 2018; 180:397-403. [DOI: 10.1111/bjd.17259] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/26/2018] [Indexed: 11/29/2022]
|
97
|
Nast A, Gaskins M, Eisert L, Werner RN, Borradori L, Marinovic B, Paul C, Dressler C. Prioritizing topics in guideline development: results of a two-phase online survey of dermatologist members of the EADV. J Eur Acad Dermatol Venereol 2018; 33:227-233. [PMID: 30317678 DOI: 10.1111/jdv.15282] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Accepted: 09/27/2018] [Indexed: 11/28/2022]
Abstract
BACKGROUND Most clinical guidelines in dermatology are encyclopaedic, covering a disease and its aetiology, diagnosis, treatment and prevention in their entirety. The usability and uptake of guideline recommendations might be improved by guidelines that are more concise and address specific questions ranked by users according to their perceived importance. OBJECTIVE To survey the largest association of dermatologists in Europe, identify which questions in their everyday practice they felt would benefit from short, evidence-based guidance and rank these systematically. METHODS A two-phase online survey using a structured ranking approach and the members directory of the European Academy of Dermatology and Venereology (EADV). RESULTS The first survey yielded 265 suggestions, indicating a response rate of 3.7%. We grouped all responses according to themes and subsequently combined these into a list of 35 broader topics. These were presented to all members of the EADV in the second survey (response rate: 9.7%), which yielded a list of the top 10 topics participants felt were most in need of guidance. The first three were 'Systemic drug treatment in dermatology during pregnancy and for women wishing to have children in the near future', 'alopecia areata' and 'interpretation of laboratory results in connective tissue diseases'. CONCLUSION Our two-phase survey of EADV members and a structured ranking process were practical to implement and yielded a list of the top 10 topics in dermatology and venereology for guideline development. Guideline dissemination needs to be improved, and practical, more concise guidelines may facilitate efforts to do so.
Collapse
|
98
|
Paul C, Teixeira L, Santos P, O’Caoimh R. IMPLEMENT A TWO-STEP SCREENING FOR COGNITIVE IMPAIRMENT IN PRIMARY CARE SERVICES IN NORTHERN PORTUGAL. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
99
|
Santos P, O’Caoimh R, Paul C, Molloy W. PORTUGUESE VERSION OF THE QUICK MILD COGNITIVE IMPAIRMENT (QMCI-P) SCREEN—RESULTS FROM THE IBIS STUDY. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
100
|
Araujo L, Teixeira L, Ribeiro O, Paul C. LOOKING AT OBJECTIVE AND SUBJECTIVE HEALTH IN CENTENARIANS: ALWAYS IN AGREEMENT? Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2570] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|